The transgenic human exon-1 R6/2 mouse HD model [13] has been mainstay for the preclinical testing of therapeutic strategies because these mice show an early-onset and rapid progression of disease accompanied by an accumulation of mutant huntingtin aggregates. Here, HTT is linked to Huntington disease.